OneMedNet's stock price soars 90% following announcement by the business platform

LootboxPhobia · 2026-02-27T15:53:37+00:00

OneMedNet's stock price rose 90% on Friday as its real-world data platform entered a new phase of commercial release. The platform converts client assessments into multi-year subscription contracts, expected to generate millions of dollars in recurring revenue for the company, driving growth in the life sciences and AI health sectors. The platform provides data access to over 2,130 healthcare institutions, combined with AI-powered search capabilities to enhance data analysis. The CEO stated that customer feedback has strengthened confidence in its platform.

LootboxPhobia

2026-02-27 15:53:37

Abstract generation in progress

Investing.com – OneMedNet Corporation (NASDAQ:ONMD) stock surged 90% on Friday after the company announced that its real-world data platform powered by Palantir Foundry has entered the next phase of commercial release.

The company stated that after showcasing real-time data sources, subscription access, and AI-driven search capabilities at the major trade show on November 10, 2025, it is converting customer evaluations into commercial subscriptions. OneMedNet reported that it is securing multi-year subscription agreements, representing millions of dollars in incremental recurring revenue, with applications in life sciences and AI health sectors continuing to grow.

The platform offers access to multimodal datasets from over 2,130 healthcare institutions. OneMedNet indicated that customer feedback since fall 2025 highlights the platform’s analytical depth in integrating clinical and longitudinal datasets, accelerated cohort feasibility analysis, and faster access for data partners.

The company’s iRWD network provides continuous connection to datasets with over 20 years of historical depth and access to data for the next three years. The platform combines AI-driven search functions with real-time data sources for evidence generation.

CEO and President Aaron Green said, “Customer feedback reinforces the platform’s performance, speed, and discovery depth. We believe this validation confirms our strategy of combining conversational AI-driven search with scalable, forward-looking data sources. As we expand subscriptions and deliver quick, intuitive value for real-world evidence generation, customer confidence is strengthened.”

OneMedNet provides compliant, AI-ready real-world data for life sciences and healthcare organizations. This commercial release advances the company’s recurring revenue model through multi-year subscription contracts.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.